Depression treatment for Coral Springs — measurement-based, 35 minutes away.

For Coral Springs, Parkland, and Coconut Creek families, RECO Health puts specialist-level depression care 35 minutes down the Sawgrass — PHP and IOP levels of care, in-house psychiatry, rTMS, IV ketamine, and Spravato on a single Delray Beach campus. Every plan is anchored to PHQ-9 trajectory rather than clinical impression, and escalation to interventional options is scheduled in advance rather than delayed by months of antidepressant cycling. That structural discipline is the difference between depression care that reaches remission and depression care that plateaus at "somewhat better."

Coral Springs sits 25 miles inland from RECO Health’s Delray Beach campus — a 35-minute drive up the Sawgrass Expressway or I-95 that puts specialist-level care within easy reach of Eagle Trace, Hidden Hammocks, Parkland Isles, Cypress Run, and Heron Bay. For families weighing whether to stay hyper-local or seek a program with in-house psychiatry, rTMS, and IV ketamine on a single campus, that half-hour drive is often the deciding factor. RECO Health delivers depression treatment built on measurement-based care — every plan begins with a DSM-5-TR formulation and a baseline PHQ-9, and every adjustment is anchored to trajectory rather than clinical impression.

Diagnostic formulation and severity staging

The initial evaluation distinguishes major depressive disorder from persistent depressive disorder (dysthymia), bipolar II depression, adjustment disorder with depressed mood, and depressive presentations secondary to hypothyroidism, chronic alcohol use, or long-standing benzodiazepine exposure. Missing bipolar II at intake is the most common — and most consequential — diagnostic error in outpatient depression care, so every intake includes MDQ screening and a longitudinal mood history before an SSRI is prescribed.

Severity staging uses the PHQ-9 as the primary anchor, supplemented by the C-SSRS for suicide risk stratification and the GAD-7 when anxious features are prominent. Labs — TSH with reflex T4, B12, folate, vitamin D, and CBC — are reviewed at intake to rule out medical contributors that would otherwise be treated with a fifth-line antidepressant. Level of care is matched to severity: partial hospitalization for PHQ-9 scores in the severe range (20+), acute suicidal ideation, or functional collapse; intensive outpatient for moderate severity with adequate outside support.

Every staged assessment is entered into the treatment record, and the PHQ-9 is repeated at least weekly. That baseline anchor is what makes escalation decisions non-arbitrary six weeks into care.

Pharmacology sequenced by evidence, not habit

First-line pharmacotherapy is an SSRI (sertraline 50-200 mg, escitalopram 10-20 mg) or SNRI (venlafaxine XR 75-225 mg, duloxetine 60-120 mg), selected on the basis of side-effect profile, drug interactions, and prior response history. Each trial is held at therapeutic dose for a full 4-6 week response window before it counts as an adequate trial. Trials cut short at two weeks because “it isn’t working yet” are the reason so many outpatients cycle through five antidepressants without a real remission.

Partial responders — meaningful movement on the PHQ-9 but not remission — are augmented before being switched. Standard augmentation options include aripiprazole 2-10 mg, lithium 600-900 mg targeted to a serum level of 0.4-0.8 mEq/L, or bupropion XL 300-450 mg added to an SSRI. Quetiapine XR is reserved for depressive presentations with prominent insomnia or anxiety; buspirone is used for residual anxious features. Non-responders — no movement after an adequate trial — are switched to a different mechanistic class rather than a same-class me-too agent.

Two failed adequate trials meets the operational definition of treatment-resistant depression. At that point, the plan pivots to interventional options rather than a sixth pharmacologic guess.

Behavioral therapy modalities with evidence for depression

Cognitive Behavioral Therapy for depression targets the specific cognitive distortions (all-or-nothing thinking, catastrophizing, personalization) and behavioral withdrawal that maintain the disorder. Behavioral Activation, which frequently equals or outperforms full-protocol CBT for severe depression, restores rewarding and mastery activities on a scheduled, graded basis rather than waiting for motivation to return. Interpersonal Therapy addresses grief, role transition, interpersonal conflict, and interpersonal deficits as depression drivers when those themes dominate the case formulation.

RECO’s therapists deliver these modalities as protocols — with fidelity to session structure, homework, and outcome tracking — not as a loose collection of therapy techniques. Acceptance and Commitment Therapy is layered in when rumination and experiential avoidance dominate the picture. Motivational Interviewing is used at intake and around ambivalence about medication adherence or program engagement.

For clients whose depression is trauma-linked — a substantial subset — Cognitive Processing Therapy or EMDR is added once affect regulation is stable enough to tolerate exposure work. DBT skills (distress tolerance, emotion regulation, interpersonal effectiveness) support clients with prominent self-harm urges or chronic suicidality.

Escalation pathway when medication and therapy aren’t enough

Approximately one-third of clients with major depression fail to achieve remission after two adequate antidepressant trials. RECO’s escalation pathway is defined in advance so that treatment-resistant presentations don’t drift for months while the same drug class is tried a third time.

For insurance-eligible TRD, repetitive transcranial magnetic stimulation is delivered to the left dorsolateral prefrontal cortex at 10 Hz — 3000 pulses per session at 120% of resting motor threshold — across the standard 36-session acute course. IV ketamine is used at 0.5 mg/kg over 40 minutes on a six-infusion induction schedule when acute suicidality or occupational collapse can’t wait six weeks for an antidepressant to work. Esketamine (Spravato) is offered where a REMS-monitored intranasal protocol is preferred over IV access or where insurance favors it.

Escalation is triggered on a schedule — reassessed every four to six weeks against PHQ-9 trajectory — not after months of drift. That structural discipline is the single largest difference between depression care that reaches remission and depression care that plateaus at “somewhat better.”

What to expect on your first visit

Intake is scheduled within 24-72 hours of the initial call and runs approximately 90 minutes. A licensed clinician completes the biopsychosocial assessment, PHQ-9, GAD-7, C-SSRS, MDQ, and substance-use screening (AUDIT, DAST-10). Where clinically indicated, a same-day or next-business-day psychiatric evaluation is arranged so that pharmacotherapy and the therapy plan are built together rather than sequentially.

The clinician issues a working DSM-5-TR diagnosis, a level-of-care recommendation grounded in ASAM Criteria dimensions where co-occurring substance use is present, and a written treatment plan naming the specific modalities, medication targets, reassessment intervals, and safety plan. Clients leave the first visit with a plan on paper, not a promise to figure it out over the coming weeks.

Insurance and admissions from Coral Springs

RECO Health is in-network with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS across most PHP and IOP product lines. Admissions verifies benefits — including PHP and IOP day limits, rTMS medical necessity criteria, and Spravato prior authorization requirements — before the first visit, and provides out-of-pocket estimates in writing.

Coral Springs, Parkland, and Coconut Creek admissions are routine. The 35-minute drive up the Sawgrass Expressway or I-95 is short enough that most PHP and IOP clients commute from home rather than relocating, keeping family, work, and school structures intact throughout treatment.

Serving residents of: Eagle Trace, Hidden Hammocks, Parkland Isles, Cypress Run, Heron Bay.